Adalimumab (TNFα Inhibitor) Therapy Exacerbates IgA Glomerulonephritis Acute Renal Injury and Induces Lupus Autoantibodies in a Psoriasis Patient
Adalimumab (Humira) is a tumour necrosis factor α (TNFα) inhibitor that is approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, and juvenile idiopathic arthritis (Sullivan and Preda (2009), Klinkhoff (2004), and Medicare Au...
Saved in:
Main Authors: | S. S. Wei, R. Sinniah |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Case Reports in Nephrology |
Online Access: | http://dx.doi.org/10.1155/2013/812781 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Association of TNF-Alpha Inhibitors and Development of IgA Nephropathy in Patients with Rheumatoid Arthritis and Diabetes
by: Vedran Premužić, et al.
Published: (2020-01-01) -
IgG, IgM, and IgA Antinuclear Antibodies in Discoid and Systemic Lupus Erythematosus Patients
by: Sheridan A. Jost, et al.
Published: (2014-01-01) -
Dimeric and polymeric IgA, but not monomeric IgA, enhance the production of IL-6 by human renal mesangial cells
by: T. J. F. Reterink, et al.
Published: (1996-01-01) -
Corticosteroids in Patients with IgA Nephropathy and Severe Chronic Renal Damage
by: Claudio Pozzi, et al.
Published: (2012-01-01) -
Association between IgG4 Autoantibody and Complement Abnormalities in Systemic Lupus Erythematosus
by: Qingjun Pan, et al.
Published: (2016-01-01)